Clinical trials: in Austria
Type 1 Diabetes
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
- Trial name
- SAFEGUARD (NCT07187531)
- Testing
- High Dose SAB-142, Low Dose SAB-142
- Where
- 68 sites in United States, Australia and 13 more
- Volunteers
- 159 people
- Sponsor
- SAb Biotherapeutics, Inc.
Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically…
- Trial name
- NCT05416307
- Testing
- ELA026
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 156 people
- Sponsor
- Electra Therapeutics Inc.
Secondary Progressive Multiple Sclerosis (SPMS)
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)
- Trial name
- REMASTER (NCT07225504)
- Testing
- Remibrutinib (blinded), Remibrutinib (Open label)
- Where
- 296 sites in United States, Argentina and 34 more
- Volunteers
- 1,275 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Neoplasms, Ovarian Cancer
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy.
- Trial name
- TroFuse-021 (NCT07318558)
- Testing
- Sacituzumab tirumotecan, Bevacizumab, Rescue Medications
- Where
- 167 sites in United States, Argentina and 28 more
- Volunteers
- 900 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps
This is a double-blind, parallel-group, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.
- Trial name
- CEREN-3 (NCT07424144)
- Testing
- Itepekimab (SAR440340)
- Where
- 46 sites in United States, Argentina and 11 more
- Volunteers
- 59 people
- Sponsor
- Sanofi
Parkinson's Disease
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.
- Trial name
- NCT02071134
- Testing
- Deep Brain Stimulation (DBS)
- Where
- 87 sites in United States, Argentina and 13 more
- Volunteers
- 1,500 people
- Sponsor
- Boston Scientific Corporation
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Heart Failure and Impaired Kidney Function
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
This is a Phase III, international, multi-centre, randomised, double-blind, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event.
- Trial name
- BalanceD-HF (NCT06307652)
- Where
- 852 sites in United States, Argentina and 37 more
- Volunteers
- 3,850 people
- Sponsor
- AstraZeneca
Sarcopenia, Liver Cirrhosis
Microbiome and Sarcopenia in Patients With Liver Cirrhosis
Protein-energy malnutrition (PEM) occurs in 65-90% of patients with liver cirrhosis. Severity of malnutrition correlates with progression of liver disease and leads to sarcopenia in 30-70% of cirrhotic patients.
- Trial name
- NCT03080129
- Testing
- Fresubin energy
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Valve Heart Disease
Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis
Transcatheter aortic valve implantation (TAVI) serves a growing spectrum of patients with symptomatic severe aortic stenosis (AS). Approximately 80% of surgical aortic valve replacements are performed using a bioprosthesis.
- Trial name
- BASELINE (NCT04843072)
- Testing
- EVOLUT R/PRO/PRO+/FX bioprosthesis, Edwards Sapien S3/Ultra bioprosthesis, MYVAL/Octacor/Octapro bioprosthesis
- Where
- 14 sites in United States, Austria and 10 more
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Extensive-Stage Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus…
- Trial name
- NCT06646276
- Testing
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin
- Where
- 183 sites in United States, Argentina and 24 more
- Volunteers
- 530 people
- Sponsor
- Bristol-Myers Squibb
Sarcopenia
Austrian Biobanking Study for Sarcopenia
The investigators aim to set up a biobanking study in Graz, Austria, to study sarcopenia in liver cirrhosis and chronic inflammatory bowel disease by collecting a standardized dataset including routine clinical and biochemical…
- Trial name
- ASGSC (NCT06632743)
- Where
- Austria
- Volunteers
- 1,000 people
- Sponsor
- Medical University of Graz
Fabry Disease
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age…
- Trial name
- PERIDOT (NCT05206773)
- Testing
- Venglustat (GZ402671)
- Where
- 50 sites in United States, Argentina and 19 more
- Volunteers
- 122 people
- Sponsor
- Sanofi
Biliary Tract Cancer
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing…
- Trial name
- DESTINY-BTC01 (NCT06467357)
- Testing
- Gemcitabine, Cisplatin, Durvalumab
- Where
- 272 sites in United States, Australia and 25 more
- Volunteers
- 620 people
- Sponsor
- AstraZeneca
Sedation Complication, Sedation During GI Endoscopy
Safety of Sedation During Interventional Endoscopy
Sedation is routinely used during interventional endoscopic procedures to improve patient comfort and optimize procedural conditions.
- Trial name
- SCOPE-SAFE (NCT07872657)
- Testing
- Sedation during interventional endoscopy
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- Medical University Innsbruck
Migraine, Headache Disorders
High-Intensity Interval Training and Progressive Muscle Relaxation as a Movement-Based Group Intervention for the Non-Pharmacological Prevention of Adolescent Migraine
Background: The prevalence of migraine during adolescence is 7.7%, affecting 9.7% of girls and 6.0% of boys. Despite its high prevalence, treatment options remain limited.
- Conditions
- Migraine, Headache Disorders, Pediatric Migraine
- Trial name
- MigraFit (NCT07850622)
- Testing
- Weekly group training
- Where
- Austria
- Volunteers
- 27 people
- Sponsor
- Medical University Innsbruck
Graft Function
Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoperative Parathyroid Insufficiency (IMIPAT Study)
Parathyroid insufficiency is a common complication in thyroid surgery and occurs in 6.6 to 24%. Up to 4.4% suffer from permanent hypoparathyroidism requiring life-time substitution of calcium and vitamin D in order to maintain a…
- Trial name
- IMIPAT (NCT07516990)
- Testing
- Intramuscular injection of mashed parathyroid tissue into the brachioradial muscle during thyroid surgery
- Where
- 2 sites in Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia
Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia
The primary objective of the trial is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based…
- Conditions
- Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
- Trial name
- NCT06376162
- Testing
- Ziftomenib, Cytarabine, Fludarabine
- Where
- 20 sites in United States, Austria and 5 more
- Volunteers
- 20 people
- Sponsor
- PedAL BCU, LLC
Sleep
Effects of Microbiome Modulation on Sleep in Working People
We aim to test whether quality of sleep in working people can be improved by modulating the gut microbiome with probiotics.
- Trial name
- Sleep (NCT05836168)
- Testing
- Omnibiotic Stress Repair
- Where
- Austria
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.